Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AMGN:US

160.3600 USD 2.4500 1.55%

As of 20:10:00 ET on 05/01/2015.

Snapshot for Amgen Inc (AMGN)

Open: 159.5000 Day's Range: 158.6500 - 161.6899 Volume: 3,260,738
Previous Close: 157.9100 52wk Range: 109.4100 - 173.6000 1-Yr Rtn: +45.41%

Stock Chart for AMGN

No chart data available.
  • AMGN:US 160.3600
  • 1D
  • 1M
  • 1Y
157.9100
Interactive AMGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AMGN

Current P/E Ratio (ttm) 20.0578
Estimated P/E(12/2015) 16.8075
Relative P/E vs. SPX 1.0846
Earnings Per Share (USD) (ttm) 7.9949
Est. EPS (USD) (12/2015) 9.5410
Est. PEG Ratio 1.6377
Market Cap (M USD) 121,925.50
Shares Outstanding (M) 760.32
30 Day Average Volume 3,525,679
Price/Book (mrq) 4.6004
Price/Sale (ttm) 5.9272
Dividend Indicated Gross Yield 1.97%
Cash Dividend (USD) 0.7900
Dividend Ex-Date 05/12/2015
5 Year Dividend Growth -
Next Earnings Announcement 07/28/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AMGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AMGN

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Robert A Bradway "Bob"Chairman/President/CEOAnnette L SuchChief Accounting Officer
David W MelineExec VP/CFOAnthony C Hooper "Tony"Exec VP:Global Commercial Ops
More Company Profile & Key Executives for AMGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil